MX346950B - Reovirus que tienen secuencias modificadas. - Google Patents
Reovirus que tienen secuencias modificadas.Info
- Publication number
- MX346950B MX346950B MX2013013938A MX2013013938A MX346950B MX 346950 B MX346950 B MX 346950B MX 2013013938 A MX2013013938 A MX 2013013938A MX 2013013938 A MX2013013938 A MX 2013013938A MX 346950 B MX346950 B MX 346950B
- Authority
- MX
- Mexico
- Prior art keywords
- reoviruses
- modified
- modified sequences
- nucleic acid
- well
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/765—Reovirus; Rotavirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/13—Tumour cells, irrespective of tissue of origin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
- C12N2720/12221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
- C12N2720/12222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
- C12N2720/12232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere a un reovirus aislado caracterizado porque comprende uno o más de los siguientes polipéptidos: a) un polipéptido sigma-3 que comprende la SEQ ID NO: 15, b) un polipéptido mu-1 que tiene al menos una modificación de aminoácidos, en donde al menos una modificación de aminoácidos comprende una Asp en el residuo 73 enumerado en relación con la SEQ ID NO: 27 (No. De Acceso al GenBank M20161.1); o c) un polipéptido mu-2 que tiene al menos una modificación de aminoácidos, en donde al menos una modificación de aminoácidos comprende una Ser en el residuo 528 enumerada en relación con la SEQ ID NO: 29 (No. De Acceso al GenBank AF461684.1). .
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US89442507P | 2007-03-12 | 2007-03-12 | |
US98956807P | 2007-11-21 | 2007-11-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX346950B true MX346950B (es) | 2017-04-06 |
Family
ID=39758956
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009009598A MX2009009598A (es) | 2007-03-12 | 2008-03-11 | Reovirus que tienen secuencias modificadas. |
MX2013013938A MX346950B (es) | 2007-03-12 | 2009-09-08 | Reovirus que tienen secuencias modificadas. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009009598A MX2009009598A (es) | 2007-03-12 | 2008-03-11 | Reovirus que tienen secuencias modificadas. |
Country Status (17)
Country | Link |
---|---|
US (5) | US7803385B2 (es) |
EP (2) | EP2132315B1 (es) |
JP (1) | JP5577103B2 (es) |
KR (1) | KR101647843B1 (es) |
CN (1) | CN103710359A (es) |
AR (1) | AR066395A1 (es) |
AU (1) | AU2008226291B2 (es) |
CA (1) | CA2678721C (es) |
DK (1) | DK2132315T3 (es) |
ES (1) | ES2548442T3 (es) |
HK (1) | HK1132761A1 (es) |
IL (4) | IL200353A (es) |
MX (2) | MX2009009598A (es) |
SG (1) | SG191602A1 (es) |
TW (1) | TW200904979A (es) |
WO (1) | WO2008110004A1 (es) |
ZA (1) | ZA200905951B (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6110461A (en) * | 1997-08-13 | 2000-08-29 | Oncolytics Biotech Inc. | Reovirus for the treatment of neoplasia |
US6136307A (en) * | 1997-08-13 | 2000-10-24 | Oncolytics Biotech Inc. | Reovirus for the treatment of cellular proliferative disorders |
EP2132315B1 (en) | 2007-03-12 | 2015-07-15 | Oncolytics Biotech Inc. | Reoviruses having modified sequences |
AU2008316276A1 (en) * | 2007-10-22 | 2009-04-30 | Oncolytics Biotech Inc. | Treatment regime for proliferative disorders |
EP2296679A4 (en) * | 2008-05-27 | 2012-03-21 | Oncolytics Biotech Inc | SUPPRESSION OF PRODUCTION OF PRO-INFLAMMATORY CYTOKINES DURING ONCOLYTIC REOVIRUS THERAPY |
US20110086005A1 (en) * | 2008-05-27 | 2011-04-14 | Oncolytics Biotech Inc. | Modulating interstitial pressure and oncolytic viral delivery and distribution |
BRPI0910185A2 (pt) * | 2008-06-26 | 2015-12-01 | Ceva Sante Animale S A | sorotipo de reovírus aviário isolado, reovírus aviário isolado, peptídeos, vacina, antisoro isolado, anticorpo isolado, método para proteção de aves, método para detecção ou quantificação de reovírus em aves, recipiente para vacinação de aves, kit para vacinação de aves, kit de diagnóstico, linhagem celular derivada da lmh |
FR2939807B1 (fr) * | 2008-12-11 | 2010-12-17 | Biomerieux Sa | Nouveau reovirus isole, procedes et kits de detection |
US9395356B2 (en) | 2009-10-02 | 2016-07-19 | The National Veterinary Institute | Piscine reovirus immunogenic compositions |
TW201233803A (en) | 2010-12-02 | 2012-08-16 | Oncolytics Biotech Inc | Lyophilized viral formulations |
JP6034798B2 (ja) | 2010-12-02 | 2016-11-30 | オンコリティクス バイオテク,インコーポレーテッド | 液体ウイルス製剤 |
EA201391605A1 (ru) * | 2011-04-29 | 2014-02-28 | Онколитикс Байотек Инк. | Способы очистки вирусов с использованием гельпроникающей хроматографии |
ES2796950T3 (es) | 2013-11-15 | 2020-11-30 | Oncolytics Biotech Inc | Virus oncolíticos y regímenes reforzados para tratamiento de cáncer |
US9660989B1 (en) | 2014-01-31 | 2017-05-23 | Google Inc. | Internet-wide identity management widget |
AU2017221592A1 (en) | 2016-02-16 | 2018-10-04 | Osaka University | Pharmaceutical composition for use in treating fibrosis |
WO2019237063A1 (en) * | 2018-06-07 | 2019-12-12 | Emory University | Modified reoviruses, particles, and uses in treating proliferative disorders |
KR102401077B1 (ko) | 2019-01-25 | 2022-05-24 | 바이로큐어 주식회사 | 다람쥐 섬유종 바이러스 및 리오바이러스를 포함하는 암 예방 또는 치료용 약학적 조성물 |
WO2022139490A1 (ko) * | 2020-12-22 | 2022-06-30 | 바이로큐어 주식회사 | 신규한 변형 레오바이러스 및 이의 용도 |
WO2023048532A1 (ko) * | 2021-09-24 | 2023-03-30 | 바이로큐어 주식회사 | 레오바이러스 기반 신규한 백신플랫폼 및 이의 용도 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
US6565831B1 (en) * | 1999-02-24 | 2003-05-20 | Oncolytics Biotech Inc. | Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders |
US6110461A (en) | 1997-08-13 | 2000-08-29 | Oncolytics Biotech Inc. | Reovirus for the treatment of neoplasia |
US6136307A (en) | 1997-08-13 | 2000-10-24 | Oncolytics Biotech Inc. | Reovirus for the treatment of cellular proliferative disorders |
TWI289158B (en) * | 2000-08-10 | 2007-11-01 | Oncolytics Biotech Inc | Method of producing infectious reovirus |
DE60142485D1 (de) | 2000-11-09 | 2010-08-12 | Oncolytics Biotech Inc | Verfahren zur Beurteilung von zellulären proliferativen Erkrankungen |
CA2430495A1 (en) * | 2000-12-01 | 2002-06-06 | University Of Ottawa | Oncolytic virus |
CA2437962C (en) * | 2001-03-16 | 2005-11-15 | Oncolytics Biotech Inc. | Method of extracting virus from cell culture |
US7163678B2 (en) * | 2002-11-07 | 2007-01-16 | Oncolytics Biotech Inc. | Reovirus for the treatment of ral-mediated cellular proliferative disorders |
WO2005111200A1 (en) * | 2004-05-17 | 2005-11-24 | Universite De Montreal | Novel strains of reoviruses and methods of uses thereof |
CA2571844A1 (en) * | 2004-06-24 | 2006-01-05 | Dnavec Research Inc. | Anticancer agent containing minus-strand rna virus |
US10260049B2 (en) * | 2005-08-01 | 2019-04-16 | Virocure, Inc. | Attenuated reovirus |
WO2008009115A1 (en) | 2006-07-18 | 2008-01-24 | Ottawa Health Research Institute | Disparate suicide carrier cells for tumor targeting of promiscuous oncolytic viruses |
EP2132315B1 (en) | 2007-03-12 | 2015-07-15 | Oncolytics Biotech Inc. | Reoviruses having modified sequences |
EP2296679A4 (en) * | 2008-05-27 | 2012-03-21 | Oncolytics Biotech Inc | SUPPRESSION OF PRODUCTION OF PRO-INFLAMMATORY CYTOKINES DURING ONCOLYTIC REOVIRUS THERAPY |
TW201233803A (en) * | 2010-12-02 | 2012-08-16 | Oncolytics Biotech Inc | Lyophilized viral formulations |
JP6034798B2 (ja) * | 2010-12-02 | 2016-11-30 | オンコリティクス バイオテク,インコーポレーテッド | 液体ウイルス製剤 |
-
2008
- 2008-03-11 EP EP08733587.3A patent/EP2132315B1/en active Active
- 2008-03-11 CN CN201310353609.2A patent/CN103710359A/zh active Pending
- 2008-03-11 JP JP2009552983A patent/JP5577103B2/ja active Active
- 2008-03-11 MX MX2009009598A patent/MX2009009598A/es active IP Right Grant
- 2008-03-11 KR KR1020097019418A patent/KR101647843B1/ko active IP Right Grant
- 2008-03-11 EP EP15176066.7A patent/EP2952583A1/en not_active Withdrawn
- 2008-03-11 SG SG2013040027A patent/SG191602A1/en unknown
- 2008-03-11 DK DK08733587.3T patent/DK2132315T3/en active
- 2008-03-11 CA CA2678721A patent/CA2678721C/en active Active
- 2008-03-11 US US12/046,095 patent/US7803385B2/en active Active
- 2008-03-11 WO PCT/CA2008/000483 patent/WO2008110004A1/en active Application Filing
- 2008-03-11 ES ES08733587.3T patent/ES2548442T3/es active Active
- 2008-03-12 AR ARP080101017A patent/AR066395A1/es unknown
- 2008-03-12 TW TW097108636A patent/TW200904979A/zh unknown
- 2008-03-14 AU AU2008226291A patent/AU2008226291B2/en active Active
-
2009
- 2009-08-12 IL IL200353A patent/IL200353A/en active IP Right Grant
- 2009-08-27 ZA ZA2009/05951A patent/ZA200905951B/en unknown
- 2009-09-08 MX MX2013013938A patent/MX346950B/es unknown
- 2009-12-22 HK HK09112061.0A patent/HK1132761A1/xx unknown
-
2010
- 2010-08-02 US US12/848,684 patent/US8691241B2/en active Active
-
2012
- 2012-08-30 IL IL221701A patent/IL221701A0/en unknown
- 2012-08-30 IL IL221700A patent/IL221700A0/en unknown
- 2012-08-30 IL IL221702A patent/IL221702A0/en unknown
-
2014
- 2014-02-13 US US14/179,840 patent/US10039827B2/en active Active
-
2018
- 2018-07-03 US US16/027,206 patent/US10596260B2/en active Active
-
2020
- 2020-02-13 US US16/790,114 patent/US11246930B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX346950B (es) | Reovirus que tienen secuencias modificadas. | |
TN2009000291A1 (en) | Inhibitors of mek | |
MX2009004862A (es) | Estabilizacion de vacunas por liofilizacion. | |
MX2010004374A (es) | Armazones proteinicos. | |
JO2778B1 (en) | Certain vehicles, installations and methods | |
NO20090596L (no) | Antivirale fosfinatforbindelser | |
MX2009008347A (es) | Oxabicicloheptanos y oxabicicloheptenos, su preparacion y uso. | |
MX2010003685A (es) | Analogos de quinolona y metodos relacionados con los mismos. | |
TW200732349A (en) | Anti-OX40L antibodies and methods using same | |
UA97502C2 (ru) | Кристаллическая твердая основа разагилина | |
PH12013502230A1 (en) | Multispecific antibodies | |
MX345909B (es) | Anticuerpos anti-fgfr3 y métodos que los utilizan. | |
TW201713640A (en) | Bruton's tyrosine kinase inhibitors | |
MX2007005221A (es) | Formas cristalinas de ascomicina y preparacion de ellas. | |
NO20090047L (no) | Anti-DLL4-antistoffer og fremgangsmater for anvendelse av disse | |
PH12013502192A1 (en) | Antibodies against human angiopoietin 2 | |
MX2012006549A (es) | Composiciones y metodos que comprenden variantes de proteasa. | |
MX2013002048A (es) | Conjugados, particulas, composiciones y metodos relacionados. | |
EA200971051A1 (ru) | Ингибиторы p70 s6 киназы | |
EA201171220A1 (ru) | Мутанты fgf21 и их применение | |
EA201200323A1 (ru) | Соединения и композиции, как ингибиторы протеинкиназы | |
MX340993B (es) | Agentes de suministro de acido fenilalquilcarboxilico. | |
TW200738751A (en) | Anti-EphrinB2 antibodies and methods using same | |
WO2008034142A3 (en) | Synthesis, methods of using, and compositions of cycloalkylmethylamines | |
MY173526A (en) | Novel anti-?5?1 antibodies and uses thereof |